Diffusely abnormal white matter converts to focal white matter lesions over time.
Diffusely abnormal white matter (DAWM) can be seen on T2-weighted images in some people with multiple sclerosis (MS) as heterogeneous bright signals with poorly defined borders. As opposed to focal white matter lesions (FWMLs), DAWM has been observed to impact myelin phospholipids. Investigators included 686 participants with relapsing-remitting (RR) MS, and 689 with secondary-progressive (SP) MS followed with imaging for at least 24 months.
Median DAWM volume was higher in SPMS than in RRMS, after correcting for age and disease duration. The yearly average DAWM to FWML conversion rates were 1.27 cm3 for SPMS and 0.80 cm3 for RRMS. Conversion was 5.41% of baseline DAWM volume for SPMS and 4.06% for RRMS. Whereas new FWMLs arose from regions …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)